Patrick M. Dillon

Collis, R. W., Gee, A. J., Dillon, P., & Warwick, M. (2024). Slimmer's Palsy Following Weight Loss Associated With Metastatic Breast Cancer: A Case Report. CUREUS JOURNAL OF MEDICAL SCIENCE, 16(1). doi:10.7759/cureus.52519

Millard, T., Brenin, C., Humphrey, C., Dhakal, A., Falkson, C., Petroni, G., . . . Dillon, P. (2024). A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer. INTERNATIONAL JOURNAL OF BREAST CANCER, 2024. doi:10.1155/2024/5515966

Tandon, M., Yacur, M., Brenin, C., & Dillon, P. (2024). Cryotherapy for prevention of chemotherapy induced peripheral neuropathy in breast cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 194. doi:10.1016/j.critrevonc.2023.104244

Schlefman, J., Brenin, C., Millard, T., & Dillon, P. (2023). Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy. MEDICAL ONCOLOGY, 41(1). doi:10.1007/s12032-023-02255-8

Jusino, S., Fadul, C. E. E., & Dillon, P. (2023). Systematic review of the management of brain metastases from hormone receptor positive breast cancer. JOURNAL OF NEURO-ONCOLOGY, 162(1), 45-57. doi:10.1007/s11060-023-04276-9

Ladwa, A., Elghawy, O., Schroen, A., Abernathy, K., Schlefman, J., & Dillon, P. (2023). Complete Response of Triple-Negative Metaplastic Carcinoma of the Breast Using Pembrolizumab. CASE REPORTS IN ONCOLOGY, 16(1), 1129-1135. doi:10.1159/000534146

Kilmartin, C., Westover, C., Raghavan, S., Dillon, P. M., & Campbell, C. A. (2023). Desmoid Tumor and Implant-Based Breast Reconstruction. CASE REPORTS IN ONCOLOGY, 16(1), 74-80. doi:10.1159/000525350

Morris, B. B., Smith, J. P., Zhang, Q., Jiang, Z., Hampton, O. A., Churchman, M. L., . . . Mayo, M. W. (2022). Replicative Instability Drives Cancer Progression. BIOMOLECULES, 12(11). doi:10.3390/biom12111570

Bidard, F. -C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., . . . Bardia, A. (2022). Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. JOURNAL OF CLINICAL ONCOLOGY, 40(28), 3246-+. doi:10.1200/JCO.22.00338

Harris, A. R., Esparza, S., Azimi, M. S., Cornelison, R., Azar, F. N., Llaneza, D. C., . . . Munson, J. M. (2022). Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.801764

Mort, J., Maheshwari, S., Basu, N., Dillon, P., Brady, K., Bear, H., & Millard, T. (2022). A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2022. doi:10.1155/2022/7295305

Dillon, P. M., Tushir-Singh, J., & Lum, L. G. (2022). Bispecific antibodies for the treatment of breast cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 22(8), 1017-1027. doi:10.1080/14712598.2021.1922665

Moore, M., Mills, A., Dillon, P., Atkins, K., & Shanes, E. (2021). Pleomorphic adenoma of the breast: A potential morphologic and molecular pitfall in the era of genomic risk stratification. CURRENT PROBLEMS IN CANCER: CASE REPORTS, 3. doi:10.1016/j.cpccr.2020.100047

Sytov, A., Brenin, C., Millard, T., Showalter, S., & Dillon, P. (2021). Long-Term Non-progression in Metastatic Breast Cancer Beyond 5 Years: Case Series and Review. CURRENT BREAST CANCER REPORTS, 13(3), 208-215. doi:10.1007/s12609-021-00410-6

Mariotti, V., Han, H., Ismail-Khan, R., Tang, S. J., Dillon, P., Montero, A. J., . . . Soliman, H. (2021). Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer A Randomized Clinical Trial. JAMA ONCOLOGY, 7(1), 61-69. doi:10.1001/jamaoncol.2020.5572

Silvestre, J., Gosse, T., Read, P., Gentzler, R., Purow, B., Asthagiri, A., . . . Fadul, C. E. (2021). Genesis of Quality Measurements to Improve the Care Delivered to Patients With Brain Metastases. JCO ONCOLOGY PRACTICE, 17(3), 146-+. doi:10.1200/OP.20.00233

Wages, N. A., Millard, T. A., Dillon, P. M., Brenin, C. M., & Petroni, G. R. (2020). Efficient dose-finding for drug combination studies involving a shift in study populations. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 17. doi:10.1016/j.conctc.2020.100519

Arora, P., Talamo, L., Dillon, P., Gentzler, R. D., Millard, T., Salerno, M., . . . Gaughan, E. M. (2020). Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. CARDIO-ONCOLOGY, 6(1). doi:10.1186/s40959-020-00076-6

Dillon, P. M., Brenin, C. M., & Slingluff, C. L. J. (2020). Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data. BREAST CANCER-TARGETS AND THERAPY, 12, 69-75. doi:10.2147/BCTT.S224758

Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., . . . Telli, M. L. (2019). Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA ONCOLOGY, 5(8), 1132-1140. doi:10.1001/jamaoncol.2019.1029

Thomas, M. H., Higgs, L. K., Modesitt, S. C., Schroen, A. T., Ring, K. L., & Dillon, P. M. (2019). Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?. JOURNAL OF GENETIC COUNSELING, 28(3), 700-707. doi:10.1002/jgc4.1044

Millard, T., Gupta, A., Brenin, C., Marshall, P., & Dillon, P. (2019). Radiographically Occult Carcinomatous Spread of Breast Cancer to the Liver: A Challenging Case. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2019. doi:10.1155/2019/4935615

Van Swearingen, A. E. D., Siegel, M. B., Deal, A. M., Sambade, M. J., Hoyle, A., Hayes, D. N., . . . Anders, C. K. (2018). LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. BREAST CANCER RESEARCH AND TREATMENT, 171(3), 637-648. doi:10.1007/s10549-018-4852-5

Dill, E. A., Dillon, P. M., Bullock, T. N., & Mills, A. M. (2018). IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. MODERN PATHOLOGY, 31(10), 1513-1522. doi:10.1038/s41379-018-0061-3

Mills, A. M., Dill, E. A., Moskaluk, C. A., Dziegielewski, J., Bullock, T. N., & Dillon, P. M. (2018). The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 42(2), 183-191. doi:10.1097/PAS.0000000000000949

Kim, Y., Dillon, P. M., Park, T., & Lee, J. K. (2018). CONCORD biomarker prediction for novel drug introduction to different cancer types. ONCOTARGET, 9(1), 1091-1106. doi:10.18632/oncotarget.23124

Dillon, P. M., Petroni, G. R., Smolkin, M. E., Brenin, D. R., Chianese-Bullock, K. A., Smith, K. T., . . . Slingluff, C. L. J. (2017). A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 5. doi:10.1186/s40425-017-0295-5

Vernali, S., Waxweiler, W. T., Dillon, P. M., Kanetsky, P. A., Orlow, I., Luo, L., . . . Thomas, N. E. (2017). Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma. JAMA DERMATOLOGY, 153(10), 1026-1031. doi:10.1001/jamadermatol.2017.2444

Jovanovic, B., Mayer, I. A., Mayer, E. L., Abramson, V. G., Bardia, A., Sanders, M. E., . . . Pietenpol, J. A. (2017). A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. CLINICAL CANCER RESEARCH, 23(15), 4035-4045. doi:10.1158/1078-0432.CCR-16-3055

Dill, E. A., Gru, A. A., Atkins, K. A., Friedman, L. A., Moore, M. E., Bullock, T. N., . . . Mills, A. M. (2017). PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages An Assessment of 245 Primary and 40 Metastatic Tumors. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 41(3), 334-342. doi:10.1097/PAS.0000000000000780

Romano, A. M., Gade, K. E., Nielsen, G., Havard, R., Harrison, J. H. J., Barclay, J., . . . Dillon, P. M. (2017). Early Palliative Care Reduces End-of-Life Intensive Care Unit (ICU) Use but Not ICU Course in Patients with Advanced Cancer. ONCOLOGIST, 22(3), 318-323. doi:10.1634/theoncologist.2016-0227

Dillon, P. M., Geroni, G. R., Horton, B. J., Moskaluk, C. A., Fracasso, P. M., Douvas, M. G., . . . Thomas, C. Y. (2017). A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Clinical Cancer Research, 23(15), 4138-4145. doi:10.1158/1078-0432.CCR-16-2942

Dillon, P. M., Petroni, G. R., Horton, B. J., Moskaluk, C. A., Fracasso, P. M., Douvas, M. G., . . . Thomas, C. Y. (2017). A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. CLINICAL CANCER RESEARCH, 23(15), 4138-4145. doi:10.1158/1078-0432.CCR-16-2942

Martin, A. N., Dillon, P. M., Jones, D. E., Brenin, D. R., & Lapides, D. A. (2017). Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2017. doi:10.1155/2017/8120689

Fanous, I., & Dillon, P. (2016). Cancer treatment-related cardiac toxicity: prevention, assessment and management. MEDICAL ONCOLOGY, 33(8). doi:10.1007/s12032-016-0801-5

Hamirani, Y., Fanous, I., Kramer, C. M., Wong, A., Salerno, M., & Dillon, P. (2016). Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. MEDICAL ONCOLOGY, 33(7). doi:10.1007/s12032-016-0797-x

Pierson, T. M., Tebit, E. V., El Sayed, A., Smolkin, M. E., & Dillon, P. M. (2016). Orbital Metastases from Breast Cancer: Retrospective Analysis at an Academic Cancer Center. BREAST JOURNAL, 22(4), 447-450. doi:10.1111/tbj.12604

Gentzler, R., Hall, R., Kunk, P. R., Gaughan, E., Dillon, P., Slingluff, C. L. J., & Rahma, O. E. (2016). Beyond melanoma: inhibiting the PD-1/PDL-1 pathway in solid tumors. IMMUNOTHERAPY, 8(5), 583-600. doi:10.2217/imt-2015-0029

Winn, J. S., Baker, M. G., Fanous, I. S., Slack-Davis, J. K., Atkins, K. A., & Dillon, P. M. (2016). Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival. ONCOLOGY, 91(3), 135-142. doi:10.1159/000447264

Blackhall, L. J., Read, P., Stukenborg, G., Dillon, P., Barclay, J., Romano, A., & Harrison, J. (2016). CARE Track for Advanced Cancer: Impact and Timing of an Outpatient Palliative Care Clinic. JOURNAL OF PALLIATIVE MEDICINE, 19(1), 57-63. doi:10.1089/jpm.2015.0272

Joshi, P., Smolkin, M. E., & Dillon, P. (2016). Role of postoperative radiation therapy in patients with adenoid cystic carcinoma: a SEER analysis. JOURNAL OF RADIATION ONCOLOGY, 5(2), 153-159. doi:10.1007/s13566-015-0234-3

Stukenborg, G. J., Blackhall, L. J., Harrison, J. H., Dillon, P. M., & Read, P. W. (2016). Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival. SUPPORTIVE CARE IN CANCER, 24(5), 2217-2224. doi:10.1007/s00520-015-3024-y

Dillon, P. M., Chakraborty, S., Moskaluk, C. A., Joshi, P. J., & Thomas, C. Y. (2016). Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 38(4), 620-627. doi:10.1002/hed.23925

Fanous, I., & Dillon, P. (2016). Paraneoplastic neurological complications of breast cancer. EXPERIMENTAL HEMATOLGY & ONCOLOGY, 5. doi:10.1186/s40164-016-0058-x

Romano, A. M., Wages, N. A., Smolkin, M., Fortune, K. L., Atkins, K., & Dillon, P. M. (2015). Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification.. Breast disease, 35(2), 103-111. doi:10.3233/bd-140396

Thomas, N. E., Kricker, A., Waxweiler, W. T., Dillon, P. M., Busam, K. J., From, L., . . . Berwick, M. (2014). Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas A Population-Based Study. JAMA DERMATOLOGY, 150(12), 1306-1314. doi:10.1001/jamadermatol.2014.1348

Sanoff, H. K., Deal, A. M., Krishnamurthy, J., Torrice, C., Dillon, P., Sorrentino, J., . . . Muss, H. B. (2014). Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(4). doi:10.1093/jnci/dju057

Dillon, P. M., Olson, W. C., Czarkowski, A., Petroni, G. R., Smolkin, M., Grosh, W. W., . . . Slingluff, C. L. J. (2014). A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2. doi:10.1186/2051-1426-2-23

Stukenborg, G. J., Blackhall, L., Harrison, J., Barclay, J. S., Dillon, P., Davis, M. A., . . . Read, P. (2014). Cancer patient-reported outcomes assessment using wireless touch screen tablet computers. QUALITY OF LIFE RESEARCH, 23(5), 1603-1607. doi:10.1007/s11136-013-0595-2

Marchetti, M. A., Noland, M. M., Dillon, P. M., & Greer, K. E. (2013). Taxane associated subacute cutaneous lupus erythematosus.. Dermatology online journal, 19(8), 19259.

Roberts, P. J., Usary, J. E., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., . . . Sharpless, N. E. (2012). Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models. CLINICAL CANCER RESEARCH, 18(19), 5290-5303. doi:10.1158/1078-0432.CCR-12-0563

Combest, A. J., Roberts, P. J., Dillon, P. M., Sandison, K., Hanna, S. K., Ross, C., . . . Zamboni, W. C. (2012). Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. ONCOLOGIST, 17(10), 1303-1316. doi:10.1634/theoncologist.2012-0274

Pritchard, J. E., Dillon, P. M., Conaway, M. R., Silva, C. M., & Parsons, S. J. (2012). A Mechanistic Study of the Effect of Doxorubicin/Adriamycin on the Estrogen Response in a Breast Cancer Model. ONCOLOGY, 83(6), 305-320. doi:10.1159/000341394

Song, Z., von Figura, G., Liu, Y., Kraus, J. M., Torrice, C., Dillon, P., . . . Rudolph, K. L. (2010). Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. AGING CELL, 9(4), 607-615. doi:10.1111/j.1474-9726.2010.00583.x